Boston, MA, July 28, 2008 Boston BioCom LLC, founded by Partners HealthCare System (Boston, MA) and a small team of pharmaceutical, biotechnology and technology veterans, today announced it has completed a $10 million Series A Preferred financing with Pfizer Inc. Boston BioCom intends to bring novel technologies out of academic and government laboratories and advance them into the clinic.

Boston BioCom's founders include an experienced management team with a successful track record in life sciences research, product development and commercialization. This $10 million will provide the initial capital for the first five identified technology platforms. At the appropriate stage, the platforms may become companies that will seek direct capital investment.

Jay B. Pieper, the Vice President for Corporate Development and Treasury Affairs of Partners Healthcare, said, "The outstanding combination of Boston BioCom's veteran management team, the investment by Pfizer, the scientific resources of our organization and the technologies that have already been mustered give Boston BioCom a great opportunity to be successful."

Frank A. Dinucci, President & CEO of Boston BioCom, said, "We are very excited about this investment by Pfizer. We aim to be a leader in biomedical technology commercialization, and we believe that we are in a position to achieve that objective. Two new biotech ventures have already been launched and more are in the offing."

back to news